NYSE:BSX - Boston Scientific Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $37.73 +0.03 (+0.08 %) (As of 05/22/2019 04:00 PM ET)Previous Close$37.70Today's Range$37.4450 - $37.8952-Week Range$29.96 - $41.00Volume3.66 million shsAverage Volume7.73 million shsMarket Capitalization$52.47 billionP/E Ratio25.67Dividend YieldN/ABeta0.83 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts. Receive BSX News and Ratings via Email Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:BSX Previous Symbol CUSIP10113710 CIK885725 Webhttp://www.bostonscientific.com/ Phone508-683-4000Debt Debt-to-Equity Ratio0.82 Current Ratio1.39 Quick Ratio1.12Price-To-Earnings Trailing P/E Ratio25.67 Forward P/E Ratio24.34 P/E Growth2.21 Sales & Book Value Annual Sales$9.82 billion Price / Sales5.34 Cash Flow$2.1834 per share Price / Cash Flow17.28 Book Value$6.64 per share Price / Book5.68Profitability EPS (Most Recent Fiscal Year)$1.47 Net Income$1.67 billion Net Margins18.08% Return on Equity24.65% Return on Assets9.88%Miscellaneous Employees32,000 Outstanding Shares1,390,653,000Market Cap$52.47 billion Next Earnings Date7/24/2019 (Estimated) OptionableOptionable Boston Scientific (NYSE:BSX) Frequently Asked Questions What is Boston Scientific's stock symbol? Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX." How were Boston Scientific's earnings last quarter? Boston Scientific Co. (NYSE:BSX) released its quarterly earnings data on Wednesday, April, 24th. The medical equipment provider reported $0.35 EPS for the quarter, missing analysts' consensus estimates of $0.36 by $0.01. The medical equipment provider earned $2.49 billion during the quarter, compared to analysts' expectations of $2.54 billion. Boston Scientific had a return on equity of 24.65% and a net margin of 18.08%. The business's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.33 earnings per share. View Boston Scientific's Earnings History. When is Boston Scientific's next earnings date? Boston Scientific is scheduled to release their next quarterly earnings announcement on Wednesday, July 24th 2019. View Earnings Estimates for Boston Scientific. What guidance has Boston Scientific issued on next quarter's earnings? Boston Scientific updated its FY19 earnings guidance on Wednesday, April, 24th. The company provided EPS guidance of $1.54-1.58 for the period, compared to the Thomson Reuters consensus estimate of $1.56. The company issued revenue guidance of +7-8% to $10.51-10.61 billion, compared to the consensus revenue estimate of $10.66 billion.Boston Scientific also updated its FY 2019 guidance to $1.54-1.58 EPS. What price target have analysts set for BSX? 22 brokers have issued 1 year price targets for Boston Scientific's shares. Their forecasts range from $36.00 to $48.00. On average, they expect Boston Scientific's stock price to reach $41.8727 in the next twelve months. This suggests a possible upside of 11.0% from the stock's current price. View Analyst Price Targets for Boston Scientific. What is the consensus analysts' recommendation for Boston Scientific? 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 hold ratings, 18 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Boston Scientific. What are Wall Street analysts saying about Boston Scientific stock? Here are some recent quotes from research analysts about Boston Scientific stock: 1. Needham & Company LLC analysts commented, "BSX announced it is acquiring the private company up front cash and commercial-based milestones. Vertiflex’s Superion system is a minimally invasive device to treat patients with lumbar spinal stenosis (LSS). BSX expects the deal to be immaterial to its adjusted EPS through 2020 and accretive thereafter. While we are a little surprised to see BSX enter the spinal surgery market, there probably are synergies with its existing pain business and we see this deal as a typical BSX transaction in which it acquires an asset allowing it to go deeper within a disease state/disorder (in this case chronic pain). We expect BSX’s string of acquisitions over the past ~18 months (including Vertiflex) to combine to provide a material benefit to its longer-term organic growth and we reiterate our Strong Buy rating." (5/13/2019) 2. BTIG Research analysts commented, "$42 Story BSX results fell short of Street expectations on a myriad of items. Heading into the print, investors anticipated the paclitaxel and mesh issues but less selling days, a temporary supply issue and a weaker Neuromod result pressured Q1 incrementally. As we anticipated in our preview, BSX guided FY19 revenue growth to the bottom half of the prior range (7-8% from 7- 9%). We revised our estimates accordingly for known pressure points and while there could be upside from high-growth segments (Structural Heart remains likely), our view is that NT significant outperformance by BSX is less likely than it was six months ago. On lower forecasts and a slightly lower multiple, we trim our PT from $45 to $42. Some investors have asked if the growth acceleration story is over. We do not think so but we do think there will be a NT slowdown before potential acceleration." (4/25/2019) 3. According to Zacks Investment Research, "Boston Scientific is suffering from significant cost escalation, which is weighing on its margins. Also, delay in LOTUS relaunch is hampering sales through 2018. Declining worldwide pacemaker sales is also hurting the CRM business. On a brighter note, the company is seeing growth across all business lines and geographies. Boston Scientific received a number of FDA approvals within the Cardiovascular group. This apart, it launched LithoVue within Urology and rolled out the GUIDE XT in Europe. We look forward to the three recent acquisitions- Claret Medical, VENITI and Augmenix. These are expected to strongly contribute to the company’s inorganic growth profile. Boston Scientific’s significant progress related to its LOTUS valve relaunch encourages us. Also, post the suspension of LOTUS valve in Europe, ACURATE TAVR continues to build momentum. Over the past three months, Boston Scientific outperformed its industry." (1/7/2019) Has Boston Scientific been receiving favorable news coverage? Media headlines about BSX stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Boston Scientific earned a news impact score of -2.0 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. Who are some of Boston Scientific's key competitors? Some companies that are related to Boston Scientific include 3M (MMM), Stryker (SYK), Becton Dickinson and (BDX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), ABIOMED (ABMD), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Novocure (NVCR) and ICU Medical (ICUI). What other stocks do shareholders of Boston Scientific own? Based on aggregate information from My MarketBeat watchlists, some companies that other Boston Scientific investors own include Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Bank of America (BAC), CVS Health (CVS), Gilead Sciences (GILD), Visa (v), Intel (INTC) and Boeing (BA). Who are Boston Scientific's key executives? Boston Scientific's management team includes the folowing people: Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 54)Mr. Daniel J. Brennan, Exec. VP & CFO (Age 53)Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 55)Mr. David A. Pierce, Exec. VP & Pres of MedSurg (Age 55)Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 46) Who are Boston Scientific's major shareholders? Boston Scientific's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.56%), BlackRock Inc. (8.30%), Wellington Management Group LLP (3.96%), Primecap Management Co. CA (3.24%), Janus Henderson Group PLC (2.74%) and Artisan Partners Limited Partnership (1.69%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Institutional Ownership Trends for Boston Scientific. Which major investors are selling Boston Scientific stock? BSX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, FMR LLC, Viking Global Investors LP, California Public Employees Retirement System, BlackRock Inc., Janus Henderson Group PLC, Morgan Stanley and Neuberger Berman Group LLC. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Desiree Ralls-Morrison, Edward F Mackey, Eric Francis Yves Thepaut, Jeffrey B Mirviss, John Bradley Sorenson, John E Sununu, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Wendy Carruthers, Xin Warren Wang and Yoshiaki Fujimori. View Insider Buying and Selling for Boston Scientific. Which major investors are buying Boston Scientific stock? BSX stock was acquired by a variety of institutional investors in the last quarter, including Third Point LLC, Marshall Wace LLP, Marshall Wace North America L.P., Renaissance Technologies LLC, Geode Capital Management LLC, AQR Capital Management LLC, Pictet Asset Management Ltd. and Assenagon Asset Management S.A.. Company insiders that have bought Boston Scientific stock in the last two years include John E Sununu and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific. How do I buy shares of Boston Scientific? Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Boston Scientific's stock price today? One share of BSX stock can currently be purchased for approximately $37.73. How big of a company is Boston Scientific? Boston Scientific has a market capitalization of $52.47 billion and generates $9.82 billion in revenue each year. The medical equipment provider earns $1.67 billion in net income (profit) each year or $1.47 on an earnings per share basis. Boston Scientific employs 32,000 workers across the globe. What is Boston Scientific's official website? The official website for Boston Scientific is http://www.bostonscientific.com/. How can I contact Boston Scientific? Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected] MarketBeat Community Rating for Boston Scientific (NYSE BSX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 765 (Vote Outperform)Underperform Votes: 660 (Vote Underperform)Total Votes: 1,425MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Are 12b-1 Fees Affecting Your Mutual Fund Performance? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.